Axon Alleges To Supreme Court FTC is Unconstitutional Over Blocked Acquisition

By Isabella Cheng, Published Feb 02, 2022, 09:43am EST (Info+)

Axon attempted to acquire a competitor but the FTC tried to block it. The matter is now at the center of a Supreme Court case where Axon alleges the FTC structure and procedures are unconstitutional and that the agency conducts "sham" hearings.

IPVM Image

In this report, IPVM examines Axon's allegations against the FTC and the acquisition that sparked this lawsuit.

Supreme ***** **** **** ****

** ******* **, ****, *** ** Supreme ***** ****** ** **** * case **** ****** ************ **** ******* against ********** ***** **********.

*** ******** *** * ******** ** a**** ** *************** ** **** ** **** ****, petitioning *** ******* ***** ** **** Axon's ****. *** **** ****** ***** is ******* **** *** ***'* ********* and ********** *** **************** *** **** the ******, ****** **** ********** "********* and *********** ** ********** ***************, *********, and ****** ******** *********," ******** "****" proceedings.

****'* *********** **** **** *** ***'* actions ** ***** ****'* **** *********** of ** ******** **********, *****.

IPVM Image

Powerhouse ******** *****

IPVM Image** * **** ** ****'* ********** to **** ******, *** ******* *** hired**** ********* *** ******* *** *** ******* Court ********. ******* *** ********* *******, a ****-******* ******** ** *** ********** of ******* (***) *** ********** *** US ******* ********** ****** *** ******* Court, **** **** ****-****. ******* ** now * ******* ** ******** & Ellis *** *** ****** **** **** 100 ***** ****** *** ** ******* Court.

January ****: **** ***** ******* **** ** **.

*** ******* *****'* ****** ***** ********* a ***** ****** ** **** *** Arizona ******** ***** *** *** ***** Circuit, ** ***** **** ****** ***** in ***** ** *** ***.

**** ********* ***-**** *********** *** ******** ***** ** ******* in ******* ****:

IPVM Image

$13 ******* ***** *********** ********

*****, *************** ****** **** *** "**** ** the **** *******", *** * **** camera ******* ******* ** **** ** a ****** **** ********, ********* ** Axon's *********** ** ******* ******** *****. In *** ****, **** ******** ***** for $** ******* ***. ***** *** allegedly "*********** *********" ** *** ****, losing $* ******* *** *****, *** failing ******* ** *** ******* *** New **** ****** ********** (****) * contract ** * ***, ************* *****.

**** **** ** *** ********* **** Vievu *** **** ** **** ** a **** ******. ***** *** ******* shopped ****** *** ******, *** ** one *** **********.

FTC ******* ** ***********

******* ***** **** ********* *** ***** acquisition, ** **** ****, *** *** alerted **** ** *** *************, ********* to ****'* *********. ******** **** **** it ********** **** *** ***'* ************* over *** ****** ** **+ ******, Axon ******* **** *** *** *** not ******* ** *** *********** *** threatened **** **** *** *******: ********* a "***** *****" ********* ** ** sued ** ** *** ************** *******.

**** ****** **** *** "***** *****" divesture ***** ****** ***** **** * clone ** **** **** ****'* *** IP:

*** *** **** *****, ** ** least ***** ****-**-**** ********, **** ****’* only **** *** ******** ********** *** to ********* * “***** *****” *********. The *** **** **** ** ***** unilaterally ******* *** ***** ** ********** from * “****” ** *** ****’* customers *** ********* (*** **** ***** won ****-***********), ****’* ************ ******** *** technology, **** *********, *** *** ********* services *** ******* ********* *** *** deemed *********.Remarkably, *** *** ********* *** ****** ** “**-********” ***** **** * ******* “*****” ** **** ***** **** ****’* *** ************ ********—something that Vievu never was nor could be without impermissible government regulation of, and unwarranted interference in, a highly-competitive marketplace. [emphasis added]

** *** ***** ****, **** *******, engaging ** ** *** ******** ************** hearing ***** ****** ** ** ******* that ** "*** *** **********."

Az. ******* ***** ******: **** ** ******* ****** ************

*** ******* ******* ********** ******* ****** ***** ****. *** ******** *** not *********** ******* ** * ******** in ****'* ********, *** ******* *** court ******** ** ****** ******* ****** jurisdiction ** *** *******:

**** *****, *******, ** *** *** appropriate ***** ** ******* ****’* ******. It ** “****** ***********” **** *** FTC *** **** ******** ******** ** preclude ******** ****** **** ********* *** type ** ************** ****** **** ***** to ***** ****.

*** ******* ***** **** **** *** appropriate ***** *** ***** ****** ** during *** ************** *******:

*******, **** **** ***** ***** ****** during *** ************** ******* *** **** renew ****, ** *********, **** ******* review ** *** ***** ** *******. Thus, **** ***** ***** ******* ****** jurisdiction **** **** ******, ****’* ******* for * *********** ********** **** ** denied, *** **** ****** **** ** dismissed.

** * ******, **** ******** ** the ***** ******** ***** ** *******, who ******** *** ******* *****'* ********.

** *** **** ********* ** *** Supreme ***** ********* *** ***** *******'* ruling, **** ********* **** ** ******* to **** **** **** *** *********** and ****** *** ***** ******. *** the ******* ******* **** *** *** enough *** *** ***, ***** "***[**] with *** ********** **** ***** **** believing ****** ** ** ***** ********* from ****** ** ********** ******** ******."

*********, *** ***'* ***** ** ****** the *********** ** ******, ** ******* in** ********* *** ***** ******* ***** ** Appeals, *** ** ****'* ****** ** the ******* *****.

Axon: ******* *********** ******

**** ********* * ***** ** *** Arizona ********* ********** *** "***'* ********** to ****'* ***********" *** *********. *** company ******* * ******* ** * healthy *** *********** ******:

*** **** **** *** ***’* ******-****** MCC ********** ** *** ******, ** least * *** *********** ***** ***** DEMS (********/**********, *********, *****, *******, *****, Visual ****/*******, *** ******* ****), * of **** **** ***** *** ********* accounts. ******, **********/******** **** * *** accounts, ********* *** *, *** ******* has *. *** *********** ***** *** Getac **** *** ***** ***-****** ******** like *** ********** ******* ****** (*,*** officers) *** *** ******* **** & Wildlife ********** (*** ********).

** *** ***** ** **********/********, **** inserted * ********, ****** **** *** FTC ******* ********'* $*** ******* ******** of **********, ******* ********'* ******* ********** presence:

** *** **** ** *** ***** acquisition, ********** *** ****’* ******* **********. In **** ****, ******** ********* ********** for $*** ******* **** *** ***’* blessing, ******* *** **** ******** *** already * ********** ********** ** *** BWC *** **** ***** **** ***** city ********** *** ***** ****** ************** of $**.* ******* ****** ****’* ** $4.3 *******. *** ********/********** *********** *** has * ***** **** ***** *********** (“MCC”) ********, ********* ******* **** **** than *,*** ***** ********, *** ** least ** ******** **** ***+ ********.

*** ******* **** ****** *** ******* that ***** **** ****** ********* **** won ***** *** ***** ***********, ** show **** *** *********** *** *** anti-competitive:

***** ************* *** **** ******* ******* Axon, **** **** **** ****. ******, post-acquisition, **** *** **** ** ***** 55 ******* **** ******** ** ***+ sworn ******** ** ** ******** *********:

  • ********** (** ****) – ********* *** Nashville ***** **, ** (*,*** ********)
  • ******* (** ****) – ********* **. Louis ****** **, ** (*** ********)
  • ********* (* ****) – ********* *********** State ****** (*,*** ********)
  • ***** (* ****) – ********* ****** PD, ** (*** ********)
  • ******** (* ****)
  • **/****** ****** (* ****)
  • ****** **** (* ****)
  • ***** (* ***) – ********** ******* Patrol (*,*** ********)
  • ****** ****** (* ***)
  • *********/***** (* ***)

**** **** ****** **** *** ****** had "*** ******** ** *****," *********** by *** ******* **** **** ****** entrants **** ***:

** ***** ********** ***********, *** ******* for *** *** **** (******* ***** markets *** *******) ***also ************* ** *** ******** ** *****. Recent entrants, including Getac and Visual Labs, have quickly gained traction. These dynamics are wholly inconsistent with any market power on Axon’s part—the company simply cannot exclude other companies from competing, or deter entry by new players, or charge supracompetitive prices. [emphasis added]

Axon: *** ******** "****" ***********

**** ******* ****** ** **** ** Vievu **** ****'* *** **, *** did ** **** ** ** ******** in ** ******** *** *******, ***** would ***** **** *** ***** ** Due *******. ******, **** ****** *** FTC's ******** ******* ******* * "****" in *** ******** ******* *********:

**** **** ** **** ******* ******* is ******* **** *** *** ******* Clause *** ******** ** *******.

*** ******* ****** *** ***'* *********** are * **** ********* ******* ** is ****** ********** ** ****** *** administrative *** ******, *** ************* ******* over *** *******, *** *** *** commissioners *** "******* *************."

Structure ******** ******* ** ** ** ************

****'* ******* ******** ** ** *** the *** ** **************** ** **** the *** *** ******* ********* **** largely *********, **** ************* ** ** *** ******************* *** ********* ***** **** "****** care **** *** **** ** ********** executed." ***** *** ********* *** ******** enforcement ** ***** "******** ********," ** must **** **** *** ******* ** remove ***** ********.

*******, **** ******* **** *** ************* are ******** **** **-**** ************ ******* and, *********, ********** **************, ** ********* of ******* **. ******, ********* **** *.*.*. **, *** *** **** *********** *** FTC, ************* *** **** ** ******* if **** *** ***** ** "************, neglect ** ****, ** *********** ** office.”

*** **** *********, *** ************* *** not ******* ** ******* ** *** President ****** * ******* ** “************, neglect ** ****, ** *********** ** office.” **** ***** *** ************* *** not *********** *********** *** ***** *******. So **** ** *** ************* **** short ** “***********,” *** ********* *** do ******* *** ***** ** *** watch, ** ****** *** **** ** disagrees **** ****.

*******, *** **** **** ************** *** judges **** *** ********* ** *** FTC ****** **** ** ******* ** the *********, *** **** ** ******* by *************, ** ****************, **** *******:

********, ******* *** ***-********* *** *** also **** ** ******* *** “**** cause” ** ********** **** ********* **********, 5 *.*.*. ****(*), (*)(*), ** ************* “dual-layer ** **********” **** ******* ********* Executive *******.

FTC ***-************ ***** ******* *** *******

*** ***'* ***-************ ***** ******* ****'* Due ******* ******, **** ********:

*** ******** ************** **********, ** ***** theFTC **** *** ** **********, *****, *** ****, violates Axon’s Due Process rights, including but not limited to depriving Axon of the ability to make its case before a neutral arbiter. [emphasis added]

*** ******* "*******[*] ** ********* **** all ****** ** ******** ********** **** operate ****** *** *** ("********") *** provide **** **********,"********* ** ******* *** ******'* ***** Information *********.

*******, **** ***** * ****** ** issues **** *** ***'* ********* *** procedures ***** *** ******* **** ******** Axon's ***** ** *** *******. *** example, **** ********** ** ****** *** ALJs, *** *** "** *** ***'* payroll" *** ********* ** *** ***. Further, ** * ******* **** ** appeal ** *** *** ********, *** commissioners, *** ***** ** *** *** defendant ** *** ***** *****, ****** appeals.

**** ***** * ****** *** ************, Joshua ******, *** ****** *** *** appeals ******* "********* *** * ****** institutional *******." ****** ******* *** **** in *** **** ** *****, ******** there *** ** ****** ** * result ** *** ******** *** *******, if *** *** ***** ** ***** of *** ***, *** *** ************* would ****** *********. *******, ** *** ALJ ********* **** *** ***, *** commission ***** ******* *** ***'* ********.

** ***** *****, ** *** ******* of ***** ***** *** ************** *** judge ***** ** ***** ** *** FTC *****, *** ********** ******** *********; and ** *** ******* ** *** cases ** ***** *** ************** *** judge ***** ** *********, *** ********** reversed. **** ** * ****** **** of ** ********* *** ****** ************* process.

** *** ***** ****, ******** **** to ******* ******* ******, ** ***** appeals ********* *** ********:

** *** ** ********, **** *** antitrust ********* ** ******* ******** ***** judges *** ******** ** *** ******* courts ** ******,plaintiffs ** *** **** ******** ***** ** * *** ******* ******* ****—******, *** *** **** ** **** ****** ** ** *******. [emphasis added]

DOJ *. *** *&* ************** - ******** ***** **********

**** **** ****** **** *** ***** to ***** ********** ** ***** ******** because *** *** *&* ****** ******* is **** ********* **** *** *** process. *** ******* **** ** ** unclear ** *** ****** *** *** FTC *** *** ****** ***** ****** investigates * ******** ******/***********:

******* *** *** *** *** **** dual-jurisdiction ** ****** *******, *** ******** have ******* * “*********” ******* ** decide ***** ****** **** *********** * merger. **** *** *****, *** ******** have ******* * ****** **informal, ***-****** ************** as to how they will divvy up merger investigations. Clearance ** ** ******, *****-*** *******. [emphasis added]

*******, **** ****** **** *** *** provides *** ****** ** ** ************* with ** ********* ***** ***** *** FTC **** ***. *** ***, ** it ***** ****** **** *** *&*, can **** *** ** ******* ***** to ****** *** ***********:

***** ****** ******* * *********** *********** is ********. *** ***’* **** ***** of ********* * *********** ****** ** to *** ** ******* *****.

**** ***** ******* ***** ****** "******* III ********* ****-******* *** *** ** allegiances ** *** ***." ** ********, FTC ************* ******** *** ********* ********* internally, ******** **** ** ** *** ALJ ** *** ** *** *** Commissioners **********:

*** *** ************ (********* *** *** voted ** *** *** *********) ** permitted ** ******* **** *** ************** hearing; ***, ** ****, ** *** appointed ** *** *** *** ** the ***’* ******* **** *******.

**** ***** * ****** ** ***** issues **** ********* ******* *** *******'* equal ********** ******, ******** **** ********* forced **** *** *** ******* *** not ******* ******* ** ***** *** undergo *** *** *******. *** *******:

  • ******* ***** *********** *** ******** ** the ******* ***** ** ******** *** Federal ***** ** ***** *********. ******* apply ** *** ************** ***********.

  • *** *** **** ******* * **** rigorous ******** ** ******* **** * merger ** *********** “************* ******* ***********,” whereas *** *** *** ******* * less ******* “****** ***********” ******** ** the ************** *******.

Timing *******

** ** ********* ******* **** *** Supreme ***** **** **** *** **** arguments **** **** *** **** *** federal **********. *** ******* ***** ** typically ** ******* **** ******* ** June/July **** ****.

**** **** ******** ** ***** **** case *** ****** ***********.

Comments (1)

** *** **** ********* ******* ************, **** **** **** ***** ****** with *** ***:

*** ******* ***** **** *** ****** the ******** ** "******* ******** ********* stripped ******* ******** ****** ** ************ over ************** ********** ** *** ***'* structure, **********, *** ********* ** ******** the ****** ** ******* ************ ** 'affirm, *******, ******, ** *** *****' the **********'* *****-***-****** ******." ******* **** jurisdiction, ******* **** ****** *** **** processes **** ******* *** **************** ****** reaching * ***** **** ****** ********* to ****** ***** ******.

******** ** ******** ** *** ********* of *** ******* *****'* **** **** in *******. * ******** ** ******** before******** ********* ** *** ***** ******* *** opinions *** ** ***** ** ****'* FTC ******** ******** **** *******://***.****.***/***.

** * ********, ** ******** ** these *******Axon ** ********** ********* ************ ** **********, which Axon might pursue if determined to be in the best interests of shareholders and customers. This could ******* * *********** ** *** ***** entity and/or related assets. While Axon continues to believe the 2018 acquisition of Vievu was lawful and a benefit to Vievu's customers, the cost, **** *** *********** ** ********** ********** ***** ************* ** ********** if achievable on terms agreeable to the FTC and Axon.

Agree
Disagree
Informative
Unhelpful
Funny
Login to read this IPVM report.
Why do I need to log in?
IPVM conducts reporting, tutorials and software funded by subscriber's payments enabling us to offer the most independent, accurate and in-depth information.
Loading Related Reports